[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525280":3},{"organization":4,"armGroups":7,"interventions":40,"overallOfficials":81,"centralContacts":85,"locations":89,"responsibleParty":252,"collaborators":46,"id":254,"slug":46,"hasResults":255,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":46,"eligibilityCriteria":259,"healthyVolunteers":255,"sex":260,"minAge":261,"maxAge":46,"enrollmentInfo":262,"targetDuration":46,"studyType":265,"phases":266,"briefSummary":269,"conditions":270,"keywords":278,"overallStatus":92,"whyStopped":46,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":289},{"fullName":5,"class":6},"Indapta Therapeutics, INC.","INDUSTRY",[8,17,21,25,30,35],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1: Single Agent IDP-023 - Single Dose","EXPERIMENTAL","NHL or MM patient treated with a single dose of IDP-023 monotherapy",[13,14,15,16],"Drug: IDP-023","Drug: Cyclophosphamide","Drug: Fludarabine","Drug: Mesna",{"label":18,"type":10,"description":19,"interventionNames":20},"Phase 1: Single Agent IDP-023 - Multiple Doses","NHL and MM patients treated with multiple doses of IDP-023 monotherapy",[13,14,15,16],{"label":22,"type":10,"description":19,"interventionNames":23},"Phase 1: Single Agent IDP-023 - Multiple Doses with IL-2",[13,24,14,15,16],"Drug: Interleukin-2",{"label":26,"type":10,"description":27,"interventionNames":28},"Phase 2: Combination IDP-023 plus rituximab","NHL patients treated with multiple doses of IDP-023 in combination with rituximab",[13,29,24,14,15,16],"Drug: Rituximab",{"label":31,"type":10,"description":32,"interventionNames":33},"Phase 2: Combination IDP-023 plus daratumumab","MM patients treated with multiple doses of IDP-023 in combination with daratumumab",[13,34,24,14,15,16],"Drug: Daratumumab",{"label":36,"type":10,"description":37,"interventionNames":38},"Phase 2: Combination IDP-023 plus isatuximab","MM patients treated with multiple doses of IDP-023 in combination with isatuximab",[13,24,14,15,16,39],"Drug: Isatuximab",[41,47,53,59,65,69,72,76],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"DRUG","IDP-023","NK cell therapy",[18,22,9,31,36,26],null,{"type":42,"name":48,"description":49,"armGroupLabels":50,"otherNames":51},"Rituximab","Anti-CD20 antibody therapy",[26],[52],"Rituxan",{"type":42,"name":54,"description":55,"armGroupLabels":56,"otherNames":57},"Daratumumab","Anti-CD38 antibody therapy",[31],[58],"Darzalex",{"type":42,"name":60,"description":61,"armGroupLabels":62,"otherNames":63},"Interleukin-2","Immune cytokine",[22,31,36,26],[64],"Proleukin",{"type":42,"name":66,"description":67,"armGroupLabels":68,"otherNames":46},"Cyclophosphamide","Lymphodepleting chemotherapy",[18,22,9,31,36,26],{"type":42,"name":70,"description":67,"armGroupLabels":71,"otherNames":46},"Fludarabine",[18,22,9,31,36,26],{"type":42,"name":73,"description":74,"armGroupLabels":75,"otherNames":46},"Mesna","Chemoprotectant",[18,22,9,31,36,26],{"type":42,"name":77,"description":55,"armGroupLabels":78,"otherNames":79},"Isatuximab",[36],[80],"Sarclisa",[82],{"name":83,"affiliation":5,"role":84},"Indapta Therapeutics, Inc.","STUDY_DIRECTOR",[86],{"name":83,"role":87,"phone":46,"phoneExt":46,"email":88},"CONTACT","TRIALS@INDAPTA.COM",[90,108,119,129,144,153,168,182,192,207,222,237],{"facility":91,"status":92,"city":93,"state":94,"zip":95,"country":96,"cosmosGeoPoint":97,"geoPoint":102,"contacts":103},"Valkyrie Clinical Trials","RECRUITING","Los Angeles","California","90670","United States",{"type":98,"coordinates":99},"Point",[100,101],-118.24368,34.05223,{"lat":101,"lon":100},[104],{"name":105,"role":87,"phone":106,"phoneExt":46,"email":107},"Myo Zaw","626-632-1963","myo.zaw@vctcare.com",{"facility":109,"status":110,"city":111,"state":112,"zip":113,"country":96,"cosmosGeoPoint":114,"geoPoint":118,"contacts":46},"Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center","WITHDRAWN","Lake Mary","Florida","32746",{"type":98,"coordinates":115},[116,117],-81.31784,28.75888,{"lat":117,"lon":116},{"facility":120,"status":92,"city":121,"state":122,"zip":123,"country":96,"cosmosGeoPoint":124,"geoPoint":128,"contacts":46},"Emory University Hospital","Atlanta","Georgia","30322",{"type":98,"coordinates":125},[126,127],-84.38798,33.749,{"lat":127,"lon":126},{"facility":130,"status":92,"city":131,"state":132,"zip":133,"country":96,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"University of Minnesota","Minneapolis","Minnesota","55455",{"type":98,"coordinates":135},[136,137],-93.26384,44.97997,{"lat":137,"lon":136},[140],{"name":141,"role":87,"phone":142,"phoneExt":46,"email":143},"Kayla Wagenmann, MN, RN, PHN","612-624-2342","wage0074@umn.edu",{"facility":145,"status":110,"city":146,"state":146,"zip":147,"country":96,"cosmosGeoPoint":148,"geoPoint":152,"contacts":46},"NYP\u002FWeill Cornell Medical Center","New York","10065",{"type":98,"coordinates":149},[150,151],-74.00597,40.71427,{"lat":151,"lon":150},{"facility":154,"status":92,"city":155,"state":156,"zip":157,"country":96,"cosmosGeoPoint":158,"geoPoint":162,"contacts":163},"Atrium Health Wake Forest Baptist","Winston-Salem","North Carolina","27157",{"type":98,"coordinates":159},[160,161],-80.24422,36.09986,{"lat":161,"lon":160},[164],{"name":165,"role":87,"phone":166,"phoneExt":46,"email":167},"Catalina Gonzalez-Pinzon","336-716-2957","cagonzal@wakehealth.edu",{"facility":169,"status":92,"city":170,"state":171,"zip":172,"country":96,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"University Hospitals Cleveland","Cleveland","Ohio","44106",{"type":98,"coordinates":174},[175,176],-81.69541,41.4995,{"lat":176,"lon":175},[179],{"name":180,"role":87,"phone":181,"phoneExt":46,"email":46},"UH Seidman Cancer Center Cancer Information Service Line","844-885-9659",{"facility":183,"status":110,"city":184,"state":185,"zip":186,"country":96,"cosmosGeoPoint":187,"geoPoint":191,"contacts":46},"Providence Cancer Institute Franz Clinic","Portland","Oregon","97213",{"type":98,"coordinates":188},[189,190],-122.67621,45.52345,{"lat":190,"lon":189},{"facility":193,"status":92,"city":194,"state":195,"zip":196,"country":96,"cosmosGeoPoint":197,"geoPoint":201,"contacts":202},"Rhode Island Hospital","Providence","Rhode Island","02903",{"type":98,"coordinates":198},[199,200],-71.41283,41.82399,{"lat":200,"lon":199},[203],{"name":204,"role":87,"phone":205,"phoneExt":46,"email":206},"Stephen Donnelly","401-444-4822","SDonnelly1@Lifespan.org",{"facility":208,"status":92,"city":209,"state":210,"zip":211,"country":96,"cosmosGeoPoint":212,"geoPoint":216,"contacts":217},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":98,"coordinates":213},[214,215],-86.78444,36.16589,{"lat":215,"lon":214},[218],{"name":219,"role":87,"phone":220,"phoneExt":46,"email":221},"Briana Smith","615-329-7449","briana.smith@scri.com",{"facility":223,"status":92,"city":224,"state":225,"zip":226,"country":96,"cosmosGeoPoint":227,"geoPoint":231,"contacts":232},"University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":98,"coordinates":228},[229,230],-95.36327,29.76328,{"lat":230,"lon":229},[233],{"name":234,"role":87,"phone":235,"phoneExt":46,"email":236},"Christy Allen","281-455-0250","callen6@mdanderson.org",{"facility":238,"status":92,"city":239,"state":240,"zip":241,"country":96,"cosmosGeoPoint":242,"geoPoint":246,"contacts":247},"NEXT Oncology Virginia","Fairfax","Virginia","22031",{"type":98,"coordinates":243},[244,245],-77.30637,38.84622,{"lat":245,"lon":244},[248],{"name":249,"role":87,"phone":250,"phoneExt":46,"email":251},"Blake Patterson","703-783-4505","bpatterson@nextoncology.com",{"type":253,"investigatorFullName":46,"investigatorTitle":46,"investigatorAffiliation":46,"oldNameTitle":46,"oldOrganization":46},"SPONSOR","100525280",false,"NCT06119685","IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","Phase 1\u002F2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","Key Inclusion Criteria:\n\n* For MM patients: Documented diagnosis of MM requiring systemic therapy and relapsed and\u002For refractory (R\u002FR) disease after ≥ 3 prior lines of therapy.\n* For NHL patients: R\u002FR disease and failed ≥ 2 lines of systemic chemotherapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy of greater than 12 weeks per the Investigator.\n\nKey Exclusion Criteria:\n\n* Impaired cardiac function or history of clinical significant cardiac disease.\n* Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.\n* Active SARS-CoV-2 infection.\n* Has untreated central nervous system, epidural tumor metastasis, or brain metastasis.","ALL","18 Years",{"count":263,"type":264},128,"ESTIMATED","INTERVENTIONAL",[267,268],"PHASE1","PHASE2","This is an open label, Phase 1\u002F2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.",[271,272,273,274,275,276,277],"NHL","Multiple Myeloma","Blood Cancer","Refractory Non-Hodgkin Lymphoma","Relapsed Non-Hodgkin Lymphoma","Refractory Multiple Myeloma","Relapsed Multiple Myeloma",[279],"Advanced Hematologic Cancers","2025-05-30",{"date":282,"type":283},"2025-06-03","ACTUAL",{"date":285,"type":283},"2023-10-25",{"date":287,"type":264},"2029-12-31",{"name":5,"class":6},12]